Competition & Markets Authority
Private hospital merger to be approved if local concerns addressed
The CMA has found that the completed merger between Circle and BMI does not raise UK-wide competition concerns but could reduce competition in 2 local areas.
Both Circle and BMI provide elective care to NHS and privately funded patients in the UK. BMI manages 52 private hospitals and clinics in the UK, while Circle currently operates 2 private hospitals in Bath and Reading and is planning to open a third hospital in Birmingham this year.
After completing its initial Phase 1 investigation, the Competition and Markets Authority (CMA) has found that the merger could result in a substantial reduction in competition between private healthcare services in Bath and Birmingham. Circle and BMI do, or will, compete closely in these cities and there are limited other competitors available for patients.
The CMA is concerned that if the businesses were to merge, patients who pay for their own healthcare in Birmingham and Bath could face higher prices and that NHS and privately funded patients could face a lower quality of service in those areas.
As part of its assessment, the CMA has taken into account the impact of the Coronavirus (COVID-19) outbreak by considering not only the current provision of private healthcare but also how this is likely to impact the opening of new hospitals both by the merged company and their competitors.
Joel Bamford, CMA Senior Director yesterday said:
If local concerns can be overcome, we will clear this merger. At the moment though, we have found that it if it goes ahead as planned, competition will be reduced and it could negatively impact patients in Bath and Birmingham.
We recognise that this is a difficult time, with private hospitals having effectively put their entire hospital capacity temporarily under the control of the NHS to deal with the Coronavirus (COVID-19) outbreak. It remains important that we protect competition between private healthcare providers and the benefits it can bring to patients.
The companies now have until Friday 17 April 2020 to address these concerns. If they are unable to do so, the deal will be referred for an in-depth Phase 2 investigation.
For more information, visit the Circle Health/BMI Healthcare merger inquiry case page.
For media enquiries, contact the CMA press office on 020 3738 6460 or firstname.lastname@example.org.
Latest News from
Competition & Markets Authority
£47m in overdraft refunds to bank customers after CMA action29/05/2020 09:20:00
In the last 2 years, the CMA has secured more than £47 million in refunds for customers whose banks failed to properly warn them about unarranged overdraft charges.
CMA investigates misleading online reviews22/05/2020 15:15:00
The CMA has launched an investigation into several major websites to see whether they are doing enough to protect shoppers from fake and misleading reviews.
Building supply companies abandon merger during CMA investigation22/05/2020 09:20:00
Kingspan has abandoned its proposed deal with Building Solutions during an in-depth CMA probe.
Update on CMA COVID-19 Taskforce21/05/2020 17:08:00
The CMA has published a second update from its COVID-19 Taskforce, which monitors and responds to competition and consumer problems arising from the pandemic.
Business Secretary confirms 9 new appointments to the CMA panel15/05/2020 10:10:10
Business Secretary Alok Sharma yesterday (14 May) confirmed 9 appointments to the Competition and Markets Authority (CMA) panel.
CMA consults on BA and American Airlines commitments07/05/2020 15:15:00
British Airways and American Airlines have offered commitments to resolve the CMA’s competition concerns over an agreement about airline routes between the UK and US.
CMA blocks sports-fashion merger07/05/2020 09:20:00
The CMA has blocked JD Sports’ purchase of close competitor Footasylum after finding it would leave shoppers worse off.
Publishing merger abandoned after CMA investigation05/05/2020 12:20:00
McGraw-Hill Education has abandoned its proposed deal with Cengage Learning after competition concerns raised by the CMA.